Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product... see more

Recent & Breaking News (NDAQ:RARE)

New Research Coverage Highlights Arthur J. Gallagher, Ultragenyx Pharmaceutical, Empire State Realty Trust, ConocoPhillips, Kilroy Realty, and NETGEAR — Consolidated Revenues, Company Growth, and Expectations for 2019

GlobeNewswire January 11, 2019

Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 Clinical Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

GlobeNewswire January 4, 2019

Ultragenyx to Present at J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2019

Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™ (burosumab injection) for the Treatment of X–linked Hypophosphatemia (XLH) in Adults and Children

GlobeNewswire December 6, 2018

Ultragenyx Announces Intent to Submit New Drug Application to U.S. FDA for UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders in Mid-2019

GlobeNewswire November 14, 2018

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire November 9, 2018

Report: Exploring Fundamental Drivers Behind AcelRx Pharmaceuticals, Fossil Group, FMC, Ultragenyx Pharmaceutical, Shenandoah Telecommunications, and Marcus & Millichap — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire November 9, 2018

Ultragenyx Reports Third Quarter 2018 Financial Results and Corporate Update

GlobeNewswire November 5, 2018

Ultragenyx to Host Conference Call for Third Quarter 2018 Financial Results and Corporate Update

GlobeNewswire October 30, 2018

Ultragenyx Announces Negative Topline Results from Phase 3 Study of UX007 in Patients with Glut1 DS with Disabling Movement Disorders

GlobeNewswire October 26, 2018

Ultragenyx Announces Exclusive License to REGENXBIO AAV Vectors to Develop Gene Therapy for CDD (CDKL5 Deficiency Disorder)

GlobeNewswire October 22, 2018

Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Brazil for the Treatment of Mucopolysaccharidosis VII

GlobeNewswire October 18, 2018

Research Report Identifies Ultragenyx Pharmaceutical, Helmerich & Payne, Buckeye Partners, Covanta Holding, Summit Midstream Partners, LP, and Seattle Genetics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

GlobeNewswire October 3, 2018

Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency and Progression to Higher Dose

GlobeNewswire September 27, 2018

Ultragenyx to Present at Jefferies Gene Therapy Summit

GlobeNewswire September 26, 2018

Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chief Operating Officer

GlobeNewswire September 17, 2018

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire August 30, 2018

Ultragenyx Announces FDA Accepts Proposal to Submit an NDA for UX007 for the Treatment of Long-Chain Fatty Acid Oxidation Disorders

GlobeNewswire August 29, 2018

Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europe for the Treatment of Mucopolysaccharidosis VII

GlobeNewswire August 27, 2018

Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update

GlobeNewswire August 2, 2018